Bal Pharma Share Price

Bal Pharma Limited, with its corporate operations in Bengaluru, functions as a pharmaceutical formulations and active pharmaceutical ingredient (API) manufacturing company in India. The company was incorporated in 1987 and is headquartered in Karnataka. Bal Pharma manufactures and markets pharmaceutical formulations and APIs in India and internationally. The company offers prescription drugs, generics, over‑the‑counter (OTC) products, intravenous infusion products, and bulk drugs. Bal Pharma exports its products to approximately 30 countries.

Bal Pharma share price today on NSE and BSE signifies how market participants react to the company’s operational performance and the overall developments in the generic pharmaceutical and API sector. The company’s financial health depends on API production volumes, formulation sales, raw material costs including chemical intermediates, capacity utilization rates, export demand, and the performance of its prescription drugs, generics, and API segments. Bal Pharma stock price is influenced by various factors such as earnings, regulatory changes from the Central Drugs Standard Control Organization (CDSCO), drug price controls under the National Pharmaceutical Pricing Authority (NPPA), and global demand for generic drugs. In the longer run, strategies such as expansion into new therapeutic segments, product portfolio diversification, and value‑added formulation development affect the stock market sentiments. All these factors need to be monitored closely to have an idea about the company’s stock price movements.

Bal Pharma live share price provides real‑time information about the last price traded, bid and ask prices, and volume traded. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the Bal Pharma live price helps in observing short term price volatility and shows how a stock moves relative to the broader pharmaceutical index. Furthermore, monitoring Bal Pharma stock price movements helps investors understand real‑time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short‑term performance, and respond to news, quarterly results, or sector trends that may influence the company’s valuation and overall investment outlook.

Bal Pharma Limited Company Fundamentals

a. Company Background

Bal Pharma Limited was incorporated in 1987 and is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company operates primarily in the pharmaceutical manufacturing segment, supplying products such as prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs across therapeutic areas including anti‑infectives, pain management, respiratory care, women’s health, diabetic care, herbal/ayurvedic preparations, anti‑hypertensive, anti‑lipidemic, skin care, bone health, cardiac care, gastrointestinal disorders, and piles/fistula treatment. Its manufacturing operations are based in India, with a corporate office located in Bengaluru, Karnataka, while its products are exported to approximately 30 countries. The company employs approximately 986 people. Over time, the company has expanded its production capacity and product portfolio to serve both domestic and international markets. Financial performance is assessed through standard metrics such as revenue growth, operating margins, and capacity utilisation. Market valuation indicators such as the P/E ratio are used by analysts for comparative assessment within the pharmaceutical manufacturing sector. Overall fundamentals are influenced by raw material availability, demand cycles in chronic and acute therapy segments, regulatory approvals, and API price fluctuations.

b. Company Product Lines

• Branded Formulations (prescription drugs, generics, OTC products)

• Active Pharmaceutical Ingredients (APIs) for anti‑histamine, platelet inhibitor, anti‑diabetic, anti‑convulsant, neuropathic pain, anti‑allergy, anti‑inflammatory, diuretic, and acne treatment

• Intravenous Infusion Products

• Diabetic Care Products (Diabend, Diabend M Group)

• Herbal/Ayurvedic Preparations (Stonex, Ashwamed, Prostowin, Suswas, Menoleap, Ayursulin)

• Cardiac Care Products (Secremet, Servace)

• Anti‑infectives, Pain Management, Respiratory Care, Women’s Health (Aziwin, Ebay, Balvibe, MNF, Ocium, Monogesic Plus Gel)

• Skin Care and Bone Health Products

• Gastrointestinal and Piles/Fistula Treatment products

• Various Dosage Forms (tablets, capsules, syrups, suspensions, ophthalmic, creams, ointments)

c. Company Revenue Model

• Domestic Formulation Sales

• Revenue generated through sales of branded and generic pharmaceutical formulations to distributors, hospitals, and retailers across India.

• API Sales

• Income from sale of active pharmaceutical ingredients to pharmaceutical manufacturers and generic drug producers.

• Export Sales

• Contribution from international customers in approximately 30 countries.

• Contract Manufacturing

• Revenue from manufacturing pharmaceutical products for third‑party clients.

Revenue performance is primarily influenced by demand for generic drugs, API price fluctuations, regulatory approvals, and competition from other pharmaceutical manufacturers.

d. Geographic Presence

• Corporate and Registered Office

• Administrative and management functions based in Bengaluru, Karnataka, India.

• Manufacturing Facilities

• Production plants located in India for formulations and APIs.

• Distribution Network

• Domestic distribution across India through pharmaceutical supply channels.

• Export Markets

• Products supplied to approximately 30 countries worldwide.

e. Key Milestones

• 1987: Incorporation of Bal Pharma Limited.

• 1995: Initial Public Offering (IPO) and listing on Bombay Stock Exchange (April 20, 1995).

• 2006: Listing on National Stock Exchange (May 8, 2006).

• Recent years: Continued focus on formulation and API portfolio expansion and export market development.

f. Industry Perspective

The pharmaceutical formulation and API manufacturing industry is capital‑intensive and closely linked to demand for generic drugs, regulatory approvals, and healthcare spending. Demand trends are influenced by disease prevalence, generic drug adoption, and insurance penetration. The industry faces fluctuations in API prices, regulatory approvals from CDSCO and international agencies, and competitive pricing from global generic manufacturers. Drug price control mechanisms under the NPPA and environmental regulations increasingly shape production practices and capital investment decisions. Companies in this sector must manage regulatory compliance, supply chain logistics, and competition while maintaining efficient manufacturing processes. These factors collectively influence financial performance and investor perception of firms like Bal Pharma.

Bal Pharma Limited Stock Market Presence: Listings and Index Representation

Bal Pharma Limited is listed on the National Stock Exchange (NSE) under the symbol BALPHARMA and on the Bombay Stock Exchange (BSE) with the scrip code 524824. Bal Pharma share price is actively traded on both exchanges. The company’s market presence is within the small‑cap segment of the market, with a market capitalization of approximately ₹115‑140 crore. Due to its size and sector focus, Bal Pharma stock price is generally tracked by investors interested in the pharmaceutical and API industry.

Bal Pharma Limited is part of several broad‑based and sector‑specific stock market indices, reflecting its position as a small‑cap pharmaceutical company in India. While it is not included in benchmark indices like the Sensex or Nifty 50, it is a constituent of wider market indices such as the BSE SmallCap index. Bal Pharma finds representation in these indices based on its market standing. This presence helps investors track the stock relative to other pharmaceutical and API manufacturing companies.

Bal Pharma Limited Stock Performance and Share Price History

Bal Pharma share price on the stock exchanges reflects its position as a pharmaceutical formulations and API manufacturer in India. Its performance is qualitatively driven by factors such as API production volumes, formulation sales, management of raw material costs including chemical intermediates, growth in export sales to approximately 30 countries, and the ability to control operational expenses. Investors compare Bal Pharma share price current movement with other pharmaceutical and API companies to assess relative strength.

These underlying factors become visible through real market movements across different time periods. Similar trends appear during earnings‑driven price changes. Broader sector strength has also supported the stock at various points. Beyond operational and sector influences, corporate actions, such as the company’s continued focus on branded formulations and API portfolio expansion, have significantly affected Bal Pharma share price movements by shaping future growth expectations. This shows how strategic initiatives may trigger short‑term swings, even within a regulatory environment influenced by CDSCO approval cycles and API price competition.

While short‑term movements respond to events and announcements, longer‑term valuation trends are better captured by Bal Pharma share price annual high and low levels, offering context beyond daily or weekly changes. A notable peak indicates stronger API demand and stable chemical prices, whereas a significant low aligns with market corrections or sector volatility. The stock has a 52‑week range of approximately ₹59.69 to ₹119.60. These extremes reflect the impact of drug pricing policies, global API price trends, and earnings visibility, providing a framework for understanding historical performance.

Bal Pharma share price behaviour mirrors the trading patterns of a small‑cap pharmaceutical company within India’s generic drug manufacturing ecosystem. The company’s diversified API portfolio spanning anti‑histamine, anti‑diabetic, anti‑convulsant, anti‑inflammatory, and other therapeutic categories, along with its branded formulation portfolio, has shaped its price history. Over the past several years, the stock has experienced periods of sharp gains followed by phases of consolidation. For instance, it delivered positive returns in certain years when demand for generic drugs increased, but recorded negative returns in other years, at times underperforming the broader small‑cap index over certain horizons. The stock has shown higher volatility compared to the overall market.

The company’s performance has closely tracked India’s generic drug demand and API price cycles. Positive momentum in Bal Pharma share price appeared when the company reported strong quarterly results, with net profit jumping 181.84% year‑on‑year to ₹194.62 lakhs in Q3 FY2026, driven by revenue growth of 20.03% to ₹8,749.48 lakhs. However, periods of high raw material costs and competitive pressure from larger API manufacturers have led to consolidation in Bal Pharma share price. Profitability has shown variability in recent quarters, with net profit declining 31.73% to ₹0.71 crore in the quarter ended September 2025 as against ₹1.04 crore during the previous quarter ended September 2024. The company’s gross margin is 48.28%, and net profit margin is 2.43%.

Despite industry disruptions, Bal Pharma shares showed resilience during the recovery phase. While the broader pharmaceutical sector faced supply chain challenges, the company’s diversified product portfolio and established export markets helped Bal Pharma share price recover from pandemic lows. The company maintains a workforce of 986 employees and continues to focus on quality and export markets.

Bal Pharma share price has declined for several recurring reasons. A drop in demand for specific formulations or APIs directly impacts production volumes and leads to selling pressure. Changes in government policy regarding drug price controls (NPPA) or import duties on chemical intermediates can also cause the stock to fall. Moreover, increases in operational costs such as chemical intermediate procurement or energy expenses without matching price increases squeeze margins, making the stock less attractive. Periods of global economic slowdown that affect healthcare spending in export markets raise concerns about API volumes, leading to price declines. Bal Pharma share price is sensitive to regulatory news; if the CDSCO issues warnings or import alerts, it can cause the stock to fall as investors adjust expectations for future growth. Broader market selloffs in small‑cap pharmaceutical stocks also pull Bal Pharma share price lower, regardless of the company’s individual performance. Lower capacity utilisation or reduced export orders directly hurts revenue, resulting in a lower valuation.

Bal Pharma Limited Investor Relevance and Role in Portfolio

Bal Pharma Limited is a holding in small‑cap and pharmaceutical sector portfolios, offering exposure to API manufacturing and generic formulations. Its inclusion in pharmaceutical indices underscores its importance in India’s generic drug manufacturing space. The company’s position as a manufacturer of APIs and branded formulations with an export presence to approximately 30 countries, together with its diversified product portfolio and established brand presence, makes it a consideration for long‑term allocations.

Bal Pharma share price is influenced by the company’s ownership structure. Bal Pharma’s equity is held by a broad mix of promoters, institutional investors, and retail investors, reflecting its standing in India’s pharmaceutical sector. Promoters hold a stable majority stake of approximately 50.86 percent, reflecting strong internal control. Top promoters include Shailesh Siroya (17.24%), Micro Labs Limited (12.64%), Anita Siroya (6.59%), Dilip Surana (4.05%), and Anand Surana (3.30%). Foreign Institutional Investors (FIIs) hold a small fraction of 0.14 percent, and their holdings have decreased from 0.23% in the previous quarter. Domestic Institutional Investors (DIIs) hold 0.00%. Mutual funds do not hold any stake in the company. The public holds the remaining stake. The company’s management includes MD & Executive Director Shailesh Dheerajmal Siroya. This investor base, with stable promoter participation, underscores the company’s role as a holding in both domestic and focused portfolios concentrating on pharmaceutical manufacturing.

Beyond fundamentals and ownership, Bal Pharma stock price is actively monitored in cash market segments, where trading volumes and delivery patterns reflect expectations on API prices, regulatory approvals, and policy actions affecting drug pricing. The stock is available for trading on both major Indian exchanges, allowing investors to take positions based on their outlook for the pharmaceutical sector. Market participants watch these trading indicators to gauge sentiment around quarterly results and policy announcements, such as changes in drug price control orders.

Technical indicators provide additional insight into short‑term momentum shifts in Bal Pharma share price. While these indicators are primarily used for near‑term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. In the short term and weekly timeframe, the stock has exhibited price movements that correlate with broader pharmaceutical sector trends. Based on available data, Bal Pharma share price has a debt‑to‑equity ratio of 196.6%, reflecting a high use of leverage. Return on equity (ROE) is 9.51%, and the book value is ₹50.32 per share. The company has a face value of ₹10 per share. The dividend yield is approximately 1.54%.

Overall, Bal Pharma stock price demonstrates higher volatility compared to the broader market, with the stock generally considered to have above average systematic risk. This makes it more sensitive to broader market movements and sector‑specific factors such as API price fluctuations, regulatory approvals, and competition in the generic drug market.

Bal Pharma Limited Sectoral Relevance and Peer Positioning

Bal Pharma Limited sector relevance stems from its four‑decade presence in the pharmaceutical industry, its position as a manufacturer of APIs and branded formulations across multiple therapeutic areas including anti‑infectives, pain management, respiratory care, women’s health, diabetic care, herbal/ayurvedic preparations, anti‑hypertensive, cardiac care, gastrointestinal disorders, skin care, and bone health, its API portfolio covering anti‑histamine, platelet inhibitor, anti‑diabetic, anti‑convulsant, anti‑inflammatory, and other categories, its export presence to approximately 30 countries, its workforce of 986 employees, and its corporate operations based in Bengaluru, Karnataka, establishing it as a focused small‑cap pharmaceutical provider supporting India’s generic drug and API ecosystem. Peer comparisons with pharmaceutical and API manufacturing companies like Indoco Remedies, Unichem Laboratories, Sequent Scientific, Strides Pharma Science, and Granules India focus on API and formulation capacity, product mix, export presence, and value‑added product diversification rather than short‑term stock moves. These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of API prices, drug price controls, and CDSCO approvals further highlights Bal Pharma positioning within India’s broader pharmaceutical manufacturing market.

Bal Pharma’s P/E ratio reflects how investors perceive the company’s earnings relative to its revenue streams from API sales and formulation sales. Based on available data, the current P/E ratio has shown variation with earnings cycles. The company’s profit after tax has shown improvement in certain quarters, with net profit in Q3 FY2026 jumping 181.84% year‑on‑year to ₹194.62 lakhs. However, quarterly performance has shown variability, with net profit declining 31.73% in the quarter ended September 2025. The company’s earnings before interest and taxes for recent periods reflected ongoing operational conditions, and the net profit margin has shown movement in recent quarters. Overall, these changes highlight how market sentiment evolved alongside the company’s operational performance in a cyclical pharmaceutical industry.

Alongside valuation, Bal Pharma earnings per share provide insight into its operational performance and income generation from API and formulation sales. Based on available data, the company reported a diluted EPS of approximately ₹0.20 to ₹3.5 across recent quarters. The trailing twelve‑month EPS stands at moderate levels. Bal Pharma EPS for the last full fiscal year was influenced by input cost pressures and competitive pricing conditions. The company has a face value of ₹10 per share. More recent quarterly performance suggests that EPS has shown improvement in certain quarters as the company benefited from operational efficiency and revenue growth.

Bal Pharma market cap highlights its position as a small‑cap player within India’s pharmaceutical sector. Based on recent data, the company’s market capitalization fluctuates within a range of approximately ₹115 crore to ₹140 crore depending on the reporting period. Bal Pharma market cap has moved in line with investor perceptions of the company’s growth potential following its expansion into new therapeutic categories. From earlier years through more recent periods, the market cap showed an increasing trend as the company expanded its API and formulation portfolio and strengthened its export presence, followed by a significant correction from its 52‑week high of ₹119.60. This pattern reflects investor confidence during favourable pharmaceutical cycles, followed by contraction during challenging periods impacted by cheap API imports and rising raw material costs. This decrease mirrors the correction in Bal Pharma share price from its annual high to recent levels.

Finally, Bal Pharma earnings trajectory demonstrates the impact of its operational execution in a competitive pharmaceutical industry. In recent fiscal years, total income showed growth supported by the core API and formulation business. Based on available data, the company’s revenue from operations increased from ₹65.64 crore in the quarter ended June 2025 to ₹87.49 crore in the quarter ended December 2025. Total income increased over the same period. Profit after tax improved in certain quarters. Quarterly performance has shown variability, with net sales of ₹139.90 crore in September 2025 quarter compared to ₹148.05 crore in September 2024 quarter. The company’s API and formulation segments have faced headwinds from fluctuating chemical intermediate prices, cheap API imports, and increased competitive pressures from larger pharmaceutical manufacturers. However, the company has expanded into new therapeutic categories over the last couple of years, including diabetic care, herbal/ayurvedic preparations, cardiac care, and gastrointestinal treatments, and expects further growth in the coming periods. These developments illustrate the growth trajectory of the generic pharmaceutical industry and the company’s position within this sector.

Over time, Bal Pharma market cap has moved in relation to pharmaceutical sector peers. The company’s earnings have followed the pattern typical of API and formulation manufacturing businesses, with revenue performance connecting directly to bulk drug demand and raw material cycles. Quarterly earnings have shown variability influenced by raw material costs and export order flow. The earnings per share figure has followed the trajectory of overall profitability. The price‑to‑earnings multiple has varied over time, reflecting changing investor expectations about demand for generic drugs. When generic drug demand picks up and chemical costs stabilize, the multiple may expand. Conversely, during periods of weak demand or rising raw material costs, the multiple may contract. Comparisons with peer pharmaceutical companies help investors understand relative valuation.

Bal Pharma Limited Summary

Bal Pharma Limited operates as a small‑cap pharmaceutical manufacturer with a four‑decade operating history, producing APIs and branded formulations for domestic and international markets. Bal Pharma share price reflects investor assessment of generic drug demand, API price cycles, and regulatory approvals. The stock trades on both NSE and BSE within the small‑cap segment. Operational performance depends on API demand and raw material costs, while Bal Pharma stock price movements are observed by market participants tracking the generic pharmaceutical sector.